Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2013
The purpose of this study is to evaluate the efficacy and safety of inotersen given for 65 weeks in participants with Familial Amyloid Polyneuropathy (FAP).
Epistemonikos ID: 00a0b07a252a00b54b7becf06139249e8a73e1d0
First added on: May 11, 2024